

Market Data

Jupiter Neurosciences, Inc. Nasdaq: JUNS

Fiscal Year	Dec. 31
Issue Price	\$1.11
Market Cap	\$36.7M
Shares Out.	33.1M
Float	15.2M
Insider Ownership	54%
Cash (mrq)	\$2.7M

Price & share data as of August 12, 2025

Auditor:

Cherry Beckaert

Legal Counsel:

Fox Rothschild

Transfer Agent:

Equiniti Trust Company

jupiterneurosciences.com

Company Overview

Jupiter Neurosciences, Inc. (Nasdaq: JUNS) is a clinical-stage pharmaceutical company pioneering treatments for neuroinflammation and rare diseases through its proprietary resveratrol delivery platform. Its lead product, JOTROL™, offers groundbreaking bioavailability—nine times greater than traditional resveratrol formulations—enabling safe, effective treatment for CNS disorders like Alzheimer's and Parkinson's. Backed by elite research partnerships and a robust clinical pipeline, including multiple Phase 2 trials expected to launch within the next 12 months, Jupiter is also leveraging JOTROL to build a category-leading position in the high-growth Longevity & Healthspan market. Through a new direct-to-consumer business launching in Q3 2025, Jupiter will commercialize three JOTROL™-powered nutraceutical products designed to generate near-term revenue and position the company for profitability as early as 2026—supporting the advancement of its pharmaceutical trials in parallel.

Investment Highlights

Groundbreaking technology platform delivering enhanced bioavailability

- JOTROL™ is the first and only resveratrol formulation to deliver therapeutic doses without gastrointestinal side effects, enabled by patented micellar technology
- Achieves 9x higher bioavailability compared to traditional resveratrol, unlocking its potential to treat CNS disorders and rare diseases effectively
- JOTROL targets key pathways including SIRT1 and NLRP3 inflammasomes—crucial to aging, neurodegeneration, and inflammation
- Protected by a strong patent estate extending through 2036, providing long-term competitive advantage

Robust clinical pipeline addressing combined \$50B+ market opportunities

- Focused on addressing significant unmet needs in CNS disorders, including Alzheimer's, Parkinson's, and rare diseases like MPS-I, Friedreich's Ataxia, and MELAS
- Advancing JOTROL™ into Phase 2a for Parkinson's (JNS115) with Zina Biopharmaceuticals and Catalent as execution and manufacturing partners
- Preparing for potential Phase 2 trial in Alzheimer's disease (JNS108)

Near-term revenue from category-defining Longevity & Healthspan products

- Launching direct-to-consumer product line in Q3 2025
- All three initial SKUs (Nugevia™ GLO, MND, PWR) feature JOTROL™ as a core active ingredient
- Aimed at becoming a leading brand in the global Longevity market—projected to exceed \$8 trillion by 2030
- Business model designed to achieve company-wide profitability by 2026, even while continuing investment in prescription drug development

Validated by high-profile strategic collaborations

- Research partnerships with Harvard University, Georgetown University, Picower Institute for Learning & Memory (MIT), and University of Miami Miller School of Medicine
- Building partnerships in Asia for licensing and commercialization, with interest driven by the region's embrace of resveratrol in traditional and modern medicine

Strong financial position

- \$1.76 million NIH funding received
- Raised gross proceeds of \$11 million in December 2024 IPO

Buy Rating and \$30 price target from Greenridge Global Equity Research

Partners



HARVARD
UNIVERSITY

GEORGETOWN
UNIVERSITY



MILLER SCHOOL
of **MEDICINE**




THE PICOWER
INSTITUTE
FOR LEARNING AND MEMORY



murdoch
children's
research
institute

Robust Development Pipeline



Value Proposition

Jupiter Neurosciences offers a high-conviction investment opportunity at the intersection of advanced science, near-term commercial execution, and long-term therapeutic innovation. The company's lead platform, JOTROL™, is a patented resveratrol formulation that overcomes the historic limitations of poor bioavailability—delivering more than nine times the absorption of traditional resveratrol with no gastrointestinal side effects. This breakthrough enables powerful application across a spectrum of CNS and metabolic conditions driven by neuroinflammation and mitochondrial dysfunction.

In parallel with its advancing clinical pipeline—including a Phase 2a trial in Parkinson's set to begin in Q3 2025—Jupiter is launching a wholly owned consumer health division targeting the global Longevity & Healthspan market. The company's first three direct-to-consumer products, expected in Q3 2025, will feature JOTROL™ as a scientifically validated core ingredient and address high-demand categories including beauty from within, cognitive health, and mitochondrial support. This initiative positions Jupiter not just as a biotech innovator, but as an emerging leader in the fast-growing \$8 trillion longevity space—with a business model designed to achieve profitability as early as 2026.

Supported by elite institutional collaborations, global expansion opportunities, and multiple upcoming inflection points, Jupiter Neurosciences offers investors a unique dual-engine growth story—one that combines the rigor of pharmaceutical development with the scalability and immediacy of a consumer brand built on clinical-grade science.

World-Class Scientific Advisory Board

Li-Huei Tsai, PhD



Li-Huei is Professor and Director of the Picower Institute for Learning and Memory at the Massachusetts Institute of Technology and one of the leading Alzheimer's researchers in the world. Actively guiding JUNS in planning of our AD studies.

Raymond Turner, MD, PhD



Professor of Neurology and Director of the Memory Disorders Program at Georgetown University Medical Center, Washington, DC. He earlier conducted an Alzheimer's trial with resveratrol generating positive data. Principal Investigator for JUNS Phase II trial in Alzheimer's Disease.

Rudolph Tanzi, PhD



Professor at Harvard and Vice-Chair of Neurology, Director of the Genetics and Aging Research Unit, and Co-Director of the Henry and Allison McCance Center for Brain Health at Massachusetts General Hospital (MGH). Regarded by many as the authority in the world for developing and predicting success in treatment of Alzheimer's.

Charbel Moussa, MBBS PhD



Associate Professor of Neurology. Director-Laboratory for Dementia and Parkinsonism. Department of Neurology Georgetown University Medical Center.

Shaun Brothers, PhD, MBA



Associate Professor at University of Miami and a Co-Founder on JUNS. Dr. Brothers is lead researcher for JUNS' pre-clinical development of rare diseases.

Claes Wahlestedt, MD, PhD



JUNS CMO, Co-Founder, and a Professor at University of Miami. Long time leading roles as research head at large pharma companies e.g., AstraZeneca and Pfizer.

W. Dalton Dietrich III, PhD



Scientific Director, The Miami Project; Kinetic Concepts Distinguished Chair in Neurosurgery; Sr. Associate Dean for Discovery Science Co-Director, Institute for Neural Engineering Professor, Neurological Surgery, Neurology, Biomedical Engineering and Cell Biology.